Rehovot-based Foamix Ltd. announced that two Institutional Review Boards reviewed and cleared its Phase I/II clinical study for Minocycline Foam in Acne patients. The Phase II multicentre clinical trial is designed to assess the safety and clinical efficacy of Foamix’s topical Minocycline Foam in patients with moderate to severe acne. The 120 patient study will be stratified into three arms, Minocycline Foam 1%, 4% or Placebo and will be treated for 12 weeks. The study will commence in Fall 2011. Foamix Ltd. is a clinical-stage, privately held specialty pharma company, focused on the development of proprietary topical foam and OilGel™ products for improved convenience, higher compliance and better efficacy.